The Outcome of Hypofractionated Stereotactic Radiosurgery for Large Vestibular Schwannomas

World Neurosurg. 2016 Sep:93:398-409. doi: 10.1016/j.wneu.2016.06.080. Epub 2016 Jun 28.

Abstract

Objectives: Stereotactic radiosurgery (SRS) for large vestibular schwannomas (VS) remains controversial. We studied the tumor local control and toxicity rates after hypofractionated SRS for VS > 3 cm.

Methods: A total of 587 patients with VS treated with SRS between 1998 and 2014 were reviewed retrospectively, and 30 Koos grade IV VSs were identified. There were 6 patients with neurofibromatosis 2 (NF2), 8 with cystic tumors, 22 with solid tumors, 19 who underwent primary CyberKnife (CK), and 11 with >3 cm after previous resection. Patients were treated by a median of 3 fractions at 18 Gy.

Results: After a median 97 months, the 3- and 10-year Kaplan-Meier estimates of local control were 85% and 80%, respectively, with 20% requiring salvage treatment. For patients who had previous tumor resection rather than primary CK, the estimates were 46% and 5%, respectively, with progression, and 3-year control rates of 71% and 94% (P = 0.008). Tumor control was also lower among NF2 versus non-NF2 patients (40% vs. 95%; P = 0.0014). Among patients with good clinical baselines before CK, 88% were functionally independent (modified Rankin Scale score, 0-2), 88% had good facial function (House-Brackmann grade I-II), and 38% had serviceable hearing (Gardner-Robertson grade I-II) at last follow-up. Hearing worsening was more likely among patients treated with primary CK (33% vs. 90%; P = 0.04).

Conclusions: Overall, 80% of large VSs were adequately controlled by CK with 97 months of median follow-up. Patients with previous surgery and NF2 also appeared to have higher rates of tumor progression, and less favorable functional outcomes.

Keywords: Cystic; Facial nerve; Hearing preservation; Hypo-fractionated stereotactic radiosurgery; Neurofibromatosis; Primary treatment; Vestibular schwannoma.

MeSH terms

  • Adult
  • Aged
  • Aged, 80 and over
  • California / epidemiology
  • Comorbidity
  • Disease-Free Survival
  • Female
  • Follow-Up Studies
  • Hearing Loss / diagnosis
  • Hearing Loss / epidemiology*
  • Hearing Loss / prevention & control*
  • Humans
  • Longitudinal Studies
  • Male
  • Middle Aged
  • Neoplasm Recurrence, Local / diagnosis
  • Neoplasm Recurrence, Local / epidemiology*
  • Neoplasm Recurrence, Local / prevention & control
  • Neuroma, Acoustic / diagnosis
  • Neuroma, Acoustic / epidemiology*
  • Neuroma, Acoustic / surgery*
  • Prevalence
  • Radiation Dose Hypofractionation*
  • Radiosurgery
  • Retrospective Studies
  • Risk Assessment
  • Treatment Outcome
  • Young Adult